Abstract
Rationale
There is evidence from research in animals and humans that the γ-aminobutyric acid B receptor subtype (GABAB) agonist baclofen may have promise as a pharmacotherapy for cocaine addiction.
Objectives
In the present study, the ability of baclofen to modify the reinforcing, subject-rated and cardiovascular effects of intranasal cocaine in humans was determined.
Methods
Non-treatment-seeking volunteers (n=7) with recent histories of cocaine use were recruited to participate in this placebo-controlled, double-blind study. Baclofen (0, 10, 20 and 30 mg) was administered orally, followed approximately 1.5 h later by intranasal cocaine (4 mg [placebo] and 45 mg). Subject-rated and cardiovascular measures were taken prior to baclofen administration and then at regular intervals after cocaine was administered. The reinforcing effects of cocaine and cocaine–baclofen combinations were assessed using the Multiple-Choice Procedure.
Results
Intranasal cocaine significantly increased the crossover point on the Multiple-Choice Procedure relative to placebo, suggesting that this cocaine dose functioned as a reinforcer. This dose of intranasal cocaine also produced increases in subject-rated effects typical of psychostimulants and elevated cardiovascular measures. The time course for the effects of cocaine was consistent with its pharmacokinetic profile following intranasal administration; increases in subject-rated and cardiovascular effects were observed almost immediately following administration and peaked at approximately 30 min. Pretreatment with baclofen had no significant effect alone, nor in combination with cocaine, on any outcome.
Conclusions
These data demonstrated that acute administration of three clinically relevant baclofen doses did not influence the acute behavioral effects of intranasal cocaine in humans.
Similar content being viewed by others
References
Abreu ME, Griffiths RR (1996) Drug tasting may confound human drug discrimination studies. Psychopharmacology 125:255–257
Brebner K, Froestl W, Andrews M, Phelan R, Roberts DCS (1999) The GABAB agonist CGP 44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology 38:1797–1804
Brebner K, Phelan R, Roberts DCS (2000) Effect of baclofen on cocaine self-administration in rats reinforced under a fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology 148:314–321
Brebner K, Childress AR, Roberts DCS (2002a) A potential role for GABAB agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 37:478–484
Brebner K, Froestl W, Roberts DCS (2002b) The GABAB agonist CGP 56433A attenuates the effect of baclofen on cocaine but not heroin self-administration in the rat. Psychopharmacology 160:49–55
Campbell UC, Lac ST, Carroll ME (1999) Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology 143:209–214
Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP (1999) Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156:11–18
Ciano PD, Everitt BJ (2003) The GABAB receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology 28:510–518
Cousins MS, Roberts DCS, de Wit H (2002) GABAB receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 65:209–220
Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston LK, Bigelow GE (1998) Development of a subjective rating scale sensitive to acute cocaine self-administration. NIDA Res Monogr 178:139
Erhardt S, Mathe JM, Chergui K, Engberg G, Svensson TH (2002) GABAB receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn Schmiedebergs Arch Pharmacol 365:173–180
Griffiths RR, Troisi JR II, Silverman K, Mumford GK (1993) Multiple-Choice Procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3–13
Griffiths RR, Rush CR, Puhala KA (1996) Validation of the Multiple-Choice Procedure for investigating drug reinforcement in humans. Exp Clin Psychopharmacol 4:97–106
Kreek MJ (1997) Goals and rationale for pharmacotherapeutic approach in treating cocaine dependence: insights from basic and clinical research. NIDA Res Monogr 175:5–35
Lile JA, Nader MA (2003) The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models. Curr Neuropharmacol 1:21–46
Ling W, Shoptaw S, Majewska D (1998) Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 18:403–404
Munzar P, Kutkat SW, Miller CR, Goldberg SR (2000) Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats. Eur J Pharmacol 408:169–174
Negus SS, Mello NK, Fivel PA (2000) Effects of GABA agonists and GABAA receptor modulators on cocaine discrimination in rhesus monkeys. Psychopharmacology 152:398–407
Nunes EV, McGrath PJ, Quitkin FM, Ocepek-Welikson K, Stewart JW, Koenig T, Wager S, Klein DF (1995) Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 39:185–195
Oliveto A, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW (1992) Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 261:885–894
Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR (2001) Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend 63:155–167
Roberts DCS, Andrews MM (1997) Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology 131:271–277
Roberts DCS, Koob GF (1982) Disruption of cocaine self-administration following 6-hydryoxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav 17:901–904
Roberts DCS, Corcoran ME, Fibiger HC (1977) On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 6:615–620
Roberts DCS, Andrews MM, Vickers GJ (1996) Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology 15:417–423
Rush CR, Baker RW (2001) Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol 9:59–73
Rush CR, Baker RW, Wright K (1999) Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Drug Alcohol Depend 55:1–12
Rush CR, Kelly TH, Hays LR, Wooten AF (2002). Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend 67:311–322
Selzer ML (1971) The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127:1653–1658
Shoaib M, Swanner LS, Beyer CE, Goldberg SR, Schindler CW (1998) The GABAB agonist baclofen modifies cocaine self-administration in rats. Behav Pharmacol 9:195–206
Shoptaw S (2000) Outcomes when using the GABAB agonist baclofen in human cocaine users. NIDA Res Monogr 180:42–43
Skinner HA (1982) The drug abuse screening test. Addict Behav 7:636–371
Stafford D, Glowa JR (2000) Effects of intravenous baclofen pretreatment on food- and cocaine-maintained responding in rhesus monkeys. Drug Alcohol Depend 60:S211
Standaert DG, Young AB (2001) Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE (eds) Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 549–568
Thummel KE, Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE (eds) Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1917–2023
United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies (2002) Emergency department trends from the Drug Abuse Warning Network, Preliminary estimates Jan-Jun 2001 with revised estimates from 1994–2000 (DAWN Series D-20, DHHS Publication No. [SMA] 02–3634). Rockville, MD, p 40
Wilkinson P, Van Dyke C, Jatlow P, Barash P, Byck R (1980) Intranasal and oral cocaine kinetics. Clin Pharmcol Ther 27:386–394
Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend 51:13–22
Yoshida M, Yokoo H, Tanaka T, Emoto H, Tanaka M (1994) Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. Brain Res 636:111–114
Acknowledgements
We would like to thank Shelly Gray, Jamie Haga, Joe Kingery, Abigail Osborne, Fran Wagner, R.N., and Allison Weber for excellent technical assistance. This research was supported by a National Institute on Drug Abuse grant DA 13567 awarded to Craig R. Rush and by a National Center for Research Resources grant M01 RR02602 awarded to the General Clinical Research Center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lile, J.A., Stoops, W.W., Allen, T.S. et al. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology 171, 441–449 (2004). https://doi.org/10.1007/s00213-003-1598-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1598-4